A method for screening and identifying immunogenic tumor neoantigens using artificial antigen-presenting cells
Through tumor whole exon sequencing and in vitro T cell stimulation detection, combined with artificial antigen presenting cells, the accuracy and simplicity of tumor neoantigen screening identification in the prior art was solved, and high accuracy and personalized treatment strategies were achieved. Establish.
Patent Information
- Application Number
- CN202410454514.8
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2024-04-16
- Publication Date
- 2024-11-19
- Estimated Expiration
- 2044-04-16
AI Technical Summary
The existing tumor neoantigens screening and identification methods require in vitro verification, with poor accuracy and cumbersome process.
Tumor whole-exon sequencing analysis, HLA and peptide affinity prediction, and detection based on vector-induced in vitro stimulation of T cell proliferation and antitumor cytokine secretion, the immunogenicity of tumor neoantigens was screened and verified by artificial antigen presenting cells.
Improve the accuracy of tumor neoantigens screening and simplify the process, establish a personalized and precise treatment strategy with scalability and low protein purity requirements.
Smart Images

Figure CN118256604B_ABST
Abstract
Description
Technical Field
[0001] The present invention belongs to the field of tumor immunology, and more specifically, relates to a method for screening and identifying immunogenic tumor neoantigens using artificial antigen presenting cells. Background Art
[0002] Tumor neoantigens are proteins produced by non-synonymous mutations in somatic cells during the development of tumor cells. This protein is only expressed in tumor tissue cells but not in normal tissues and cells, and is a specific target for tumor immunotherapy. However, not all tumor mutated peptides can become tumor neoantigens. Only mutated peptides that can effectively stimulate T cell responses can be called tumor neoantigens. Tumors are highly heterogeneous, and how to quickly and accurately predict, screen and identify tumor neoantigens is the key in the early stages.
[0003] At present, the existing methods for identifying new antigens are mainly to identify tumor somatic mutant genes by comparing the exon sequences of patient tumor tissues and normal tissues, and then predict the affinity of tumor mutant peptides in combination with the type of patient major histocompatibility complex molecules, namely human leukocyte antigen types, to preliminarily obtain candidate new antigens. Since there are a large number of false positive results in the prediction of mutant peptides, subsequent in vivo and in vitro experiments are required to verify the new tumor antigens. Based on the above analysis, a tumor new antigen screening and verification system can be established to obtain tumor new antigens, providing a basis for the establishment of a personalized and precise treatment strategy based on patients. Summary of the invention
[0004] The present invention solves the technical problems in the prior art that the tumor neoantigen screening and identification methods require in vitro and in vivo verification, have poor accuracy, and are cumbersome processes, and provides a high-throughput immunogenic tumor neoantigen screening and identification method. The present invention combines tumor whole exome sequencing analysis, HLA and peptide affinity prediction, and vector-based in vitro stimulation of T cell proliferation and anti-tumor cytokine secretion detection to accurately screen neoantigens and verify their immunogenicity. The immunogenic tumor neoantigen screening of the present invention has high accuracy and is simple to operate.
[0005] According to the purpose of the present invention, a high-throughput immunogenic tumor neoantigen screening and identification method is provided, comprising the following steps:
[0006] (1) performing exon sequencing of tumor specimens and non-tumor specimens, wherein the non-tumor specimens are adjacent tissues or peripheral blood; using the exon sequencing results of the non-tumor specimens as a control, eliminating germline mutations to obtain tumor somatic mutations; performing human leukocyte antigen typing on the tumor specimens, and comparing the mutant polypeptides obtained from the tumor somatic mutations with the typing results of the human leukocyte antigen typing to obtain human leukocyte antigen-restricted neoantigens;
[0007] (2) constructing a plasmid, wherein the plasmid contains the heavy chain and light chain genes of the human leukocyte antigen described in step (1) and also contains a Flag tag; expressing the plasmid to obtain a fusion protein of the human leukocyte antigen and the Flag tag; loading the fusion protein and an antibody of a T cell co-stimulatory signal onto microspheres to construct an artificial antigen presenting cell;
[0008] (3) incubating the human leukocyte antigen-restricted neoantigen obtained in step (1) and the artificial antigen-presenting cells obtained in step (2) so that the human leukocyte antigen-restricted neoantigen is loaded onto the human leukocyte antigen of the artificial antigen-presenting cells, and then co-incubating with T cells, wherein the surface of the T cells has the same human leukocyte antigen as the tumor specimen;
[0009] If the T cells proliferate and cytotoxic cytokine secretion is detected, the human leukocyte antigen-restricted neoantigen is an immunogenic tumor neoantigen;
[0010] If the T cells do not proliferate and / or no cytokine secretion is detected, the human leukocyte antigen-restricted new antigen is a non-immunogenic tumor new antigen.
[0011] Preferably, the tumor specimen is a lung adenocarcinoma specimen, a liver cancer specimen or a colorectal cancer specimen.
[0012] Preferably, the Flag tag is 3×Flag.
[0013] Preferably, the antibody against T cell co-stimulatory signals is mouse anti-human CD28 antibody.
[0014] Preferably, the microspheres are sulfate latex microspheres or phospholipid microspheres.
[0015] In general, the above technical solution conceived by the present invention has the following technical advantages compared with the prior art:
[0016] (1) The multiple screening and verification system of the present invention ensures the stability and accuracy of experimental results: This study combines tumor whole exome sequencing analysis, HLA and peptide affinity prediction, and detection of T cell proliferation and anti-tumor cytokine secretion stimulated by HLA-A2 / aAPCs in vitro, providing a new method for accurate screening of new antigens and verification of their immunogenicity.
[0017] (2) The HLA-A2 / aAPCs of the present invention are easy to use: HLA-A2 is a human leukocyte antigen type that covers about 50% of the population. After being loaded onto sulfate latex microspheres, it forms artificial antigen presenting cells, namely aAPCs. This product can be prepared in advance, which is convenient for storage and transportation, and can be used for in vitro verification experiments of new antigens for different individuals.
[0018] (3) The present invention establishes a precise treatment strategy based on patient personalization: individualized exon data analysis and new antigen peptide library enable screening of new antigen peptides with specific individual immunogenicity.
[0019] (4) The present invention is scalable: the system has low requirements for the expression amount and purity of HLA molecules and can be easily expanded from HLA-A2 to other HLA types, providing a reference for the preparation of aAPCs of various HLA types and the establishment of a new antigen immunogenicity identification system.
[0020] (5) The present invention has low requirements for the purity of protein molecules: the yield of HLA-A2 expression protein obtained by the insect expression system established in this study is not very high, and it is unable to provide sufficient fusion protein for large-scale preparation and purification. However, the preparation method of HLA-A2 / aAPCs established in this study does not require protein purification, and the Flag tag of the HLA-A2 fusion protein can be specifically bound to the microbeads coated with anti-Flag antibodies to promote the enrichment of the HLA-A2 fusion protein on the surface of the microbeads. BRIEF DESCRIPTION OF THE DRAWINGS
[0021] Figure 1 These are the somatic mutation characteristics of cancer tissues and the results of tumor clonal heterogeneity: A is the mutation type spectrum; B is the mutation spectrum heat map.
[0022] Figure 2 This is a diagram for screening HLA-A2 restricted new antigens of the present invention.
[0023] Figure 3 pFastBac TM Schematic diagram of the construction of Dual+[β2m+HLA-A2-3×Flag] expression plasmid.
[0024] Figure 4 The figure is a flow chart for establishing the HLA-A2 / aAPCs in vitro stimulation system of the present invention.
[0025] Figure 5 These are the results of in vitro stimulation experiments on the immunogenicity of the new antigens of the present invention. DETAILED DESCRIPTION
[0026] In order to make the purpose, technical solutions and advantages of the present invention more clearly understood, the present invention is further described in detail below in conjunction with the accompanying drawings and embodiments. It should be understood that the specific embodiments described herein are only used to explain the present invention and are not intended to limit the present invention. In addition, the technical features involved in the various embodiments of the present invention described below can be combined with each other as long as they do not conflict with each other.
[0027] The present invention uses artificial antigen presenting cells to screen and identify immunogenic tumor neoantigens, comprising the following steps:
[0028] 1. Exome sequencing of tumor specimens and adjacent adjacent or peripheral blood specimens
[0029] Lung adenocarcinoma samples from different locations of the same patient were collected. Paracancerous tissues or peripheral blood of the corresponding patients were collected as controls to eliminate germline mutations and obtain tumor somatic mutations. Tumor exome sequencing results were obtained through whole exome sequencing and library construction and bioinformatics analysis were performed.
[0030] 1.1 Library construction and library building;
[0031] 1.2 Whole exome sequencing data quality control;
[0032] 1.3 Statistical analysis of somatic mutation characteristics of cancer tissues and comparison of tumor clonal heterogeneity;
[0033] 1.4 Screening of drug treatment targets, driver genes, susceptibility genes and oncogenic signaling pathways;
[0034] 1.5 Human leukocyte antigen (HLA) typing results of the specimen;
[0035] 1.6 HLA-A2 human leukocyte restricted neoantigen screening;
[0036] 2. Expression of Flag-tagged HLA-A2 fusion protein and construction of HLA-A2 / aAPCs
[0037] 2.1pFastBac TM Dual+[β2m+HLA-A2-3×Flag] plasmid construction;
[0038] 2.2 Identification of recombinant bacmids;
[0039] 2.3 Recombinant bacmid extraction and transfection;
[0040] 2.4 Identification of HLA-A2 fusion protein by ELISA;
[0041] 2.5 Flow cytometry identification of HLA-A2 fusion protein;
[0042] 2.6 Construction of HLA-A2 / aAPCs;
[0043] 3. In vitro stimulation experiment of new antigen immunogenicity
[0044] 3.1 Isolation of human peripheral blood mononuclear cells;
[0045] 3.2 Human peripheral blood HLA-A2 flow cytometry typing test;
[0046] 3.3 CFSE labeling and staining of effector cells;
[0047] 3.4 Experiment on in vitro stimulation of HLA-A2+ healthy individual lymphocytes by candidate new antigens;
[0048] 3.5CBA was used to detect the secretion of IFN-γ cytokine.
[0049] The following are specific embodiments
[0050] Example 1
[0051] 1. Exome sequencing of tumor specimens and adjacent paracancerous specimens
[0052] 1.1 Library construction and library building
[0053] The genomic DNA of the sample to be tested is randomly interrupted by a fragmentation instrument, so that it is divided into many fragments with a length of 180-280bp. Next, the library is constructed using the Agilent human exon kit, and the fragments are end-repaired, phosphorylated, and A-tailed. Then, the adapters are connected to the two ends of each fragment, the DNA library is prepared, and the effective concentration value in the library is accurately measured using the Q-PCR method.
[0054] 1.2 Whole exome sequencing data quality control
[0055] Compare the base quality value distribution at each position of the read, the overall quality value distribution of the base, and the base distribution ratio at each position of the read. The purpose is to analyze the degree of base separation, GC content distribution, N content at each position of the read, whether the read also contains the sequencing adapter sequence, and the read repetition rate introduced by the amplification process of the experiment.
[0056] 1.3 Statistical analysis of somatic mutation characteristics in cancer tissues and comparison of tumor clonal heterogeneity
[0057] The high-quality sequences obtained by sequencing are aligned to the human reference genome, the mutation information of germline genes in the tumor samples is detected, and the presence of false positive data is reduced by eliminating the background mutations of the samples through the germline mutations of the samples, and somatic mutations are detected for paired cancer samples, and finally the detected mutations are analyzed. This embodiment includes 4 tumor samples from the same patient, and the 4 samples have different infiltration characteristics, so subsequent tumor clone heterogeneity comparison is required. MuTect2
[20] software is used to compare tumor tissue with adjacent tissue or peripheral blood to filter out germline mutations, obtain mutation information of somatic cells in tumor tissue, and obtain vcf result files for sample annotation using vep
[21] software.
[0058] Figure 1 These are the somatic mutation characteristics of cancer tissues and the results of tumor clonal heterogeneity: A is the mutation type spectrum; B is the mutation spectrum heat map.
[0059] 1.4 Screening of drug treatment targets, driver genes, susceptibility genes and oncogenic signaling pathways
[0060] Analyze the genome or exome of the tumor to discover new driver gene mutations. Detect some genes related to cancer susceptibility to discover individual sensitivity to cancer. Detect gene expression profiles or genotyping related to prognosis in specific cancers to assess the risk of recurrence and metastasis. The drug treatment targets, driver genes, susceptibility genes and carcinogenic signaling pathways obtained through screening can provide a theoretical basis for the subsequent personalized treatment of the mutant genes screened out.
[0061] 1.5 HLA typing results of the specimens
[0062] The main chromosomes were selected for genome alignment to avoid the influence of polymorphism and high complexity of the HLA region on the analysis of sequencing results.
[0063] 1.6 Analysis of tumor mutation burden, number of neoantigens, and HLA-A2-restricted neoantigen screening
[0064] The number of somatic mutations in the tumor genome after removing germline mutations is called tumor mutation load. About 10% of non-synonymous mutations can produce mutant peptides that bind to MHC with high affinity, and 1% of them can be screened for new antigen peptides that can be recognized by T cells in tumor patients.
[0065] Figure 2 This is a HLA-A2 restricted neoantigen screening diagram of the present invention. By predicting the affinity of the restricted neoantigen to human leukocyte antigen, 7 candidate neoantigen polypeptides with the strongest binding ability were screened out from 30 mutant polypeptides.
[0066] 2. Expression of Flag-tagged HLA-A2 fusion protein and construction of HLA-A2 / aAPCs
[0067] 2.1pFastBac TM Dual+[β2m+HLA-A2-3×Flag] plasmid construction
[0068] pFastBac TM Dual plasmid and β2m gene digestion and ligation, pFastBac TM Dual+[β2m] plasmid extraction, pFastBac TM Dual+[β2m] and [HLA-A2-3×Flag] gene digestion and ligation, pFastBac TM Dual+[β2m]+[HLA-A2-3×Flag] plasmid extraction.
[0069] Figure 3pFastBac TM Schematic diagram of the construction of Dual+[β2m+HLA-A2-3×Flag] expression plasmid. Figure 3 As shown in Figure 2, the light chain gene β2m and the heavy chain fusion gene HLA-A2-3×Flag were cloned into the insect expression vector pFastBac TM Dual Pp10 and Pph promoters form pFastBac TM Dual+[β2m+HLA-A2-3×Flag] recombinant plasmid.
[0070] 2.2 Identification of recombinant bacmid
[0071] pFastBac TM Dual+[β2m+HLA-A2-3×Flag] was added to the DH10Bac competent state, and the bacterial culture dish was placed in a 37°C bacterial culture incubator. After 3 days, a single white colony was selected and added to a liquid LB medium containing tetracycline (10μg / ml), kanamycin (50μg / ml) and gentamicin (7μg / ml), and cultured overnight at 37°C and 250rpm in a bacterial shaker. Repeat the steps of selecting colonies and shaking the bacteria, and use M13 primer PCR to identify whether the target gene is successfully inserted.
[0072] 2.3 Recombinant bacmid extraction and transfection
[0073] Take the overnight culture solution to extract the recombinant bacmid, detect the solution with a Nano drop instrument, and mark the concentration. Inoculate 1×10 6 SF9 cells were plated in a six-well plate, 16 μg Bacmid and 8 μl Transfection reagent were added, and the culture medium was collected for 5 days at 27°C to obtain the first generation of baculovirus P1. SF9 cells were infected according to the above steps until the maximum yield of the expressed target protein was detected.
[0074] 2.4 Identification of HLA-A2 fusion protein by ELISA
[0075] The capture antibody (W6 / 32 antibody) was placed in a well plate at 4°C for overnight coating and then blocked. 100 μl of sample was added to each well, and HRP-β2m antibody was added. After washing, TMB was added for color development and the OD value was measured. The highest OD value can be detected when the target protein yield is the highest.
[0076] 2.5 Flow cytometry identification of HLA-A2 fusion protein
[0077] Mouse anti-Flag antibody was incubated with sulfate latex microbeads for 24 hours, then washed and blocked with 3% BSA for 24 hours, then washed and incubated with HLA-A2 protein for 24 hours, then washed again and 1 μl of sulfate latex microbeads was added to 50 μl PBS, and 0.5 μl of FITC-labeled mouse anti-human HLA-A2 antibody was added for flow cytometry detection. The positive rate detected by flow cytometry should be greater than 95%.
[0078] 2.6 Construction of HLA-A2 / aAPCs
[0079] Mouse anti-Flag antibody and mouse anti-human CD28 antibody were co-incubated with sulfate latex microbeads for 24 hours, and then washed and blocked with 3% BSA for 24 hours. After washing, HLA-A2 protein was added and incubated for 24 hours, and then washed again and dissolved in PBS for storage.
[0080] 3. In vitro stimulation experiment of new antigen immunogenicity
[0081] 3.1 Isolation of human peripheral blood mononuclear cells, including T cells
[0082] The blood sample was mixed with PBS at an equal volume of 1:1, and lymphocyte separation solution was added for gradient centrifugation at room temperature for 25 minutes. The gray-white lymphocyte layer in the middle was aspirated and transferred to a test tube. After filling with PBS, it was washed twice and then 1640 culture medium containing 10% FBS was added.
[0083] 3.2 Flow cytometry of HLA-A2 in human peripheral blood
[0084] Human peripheral blood was added with red blood cell lysis buffer to lyse red blood cells at room temperature, and then washed with PBS and then stained with anti-HLA-A2 antibody and anti-human CD3 antibody for flow cytometry identification.
[0085] 3.3 CFSE staining of effector cells
[0086] PBMCs were stained with CFSE staining solution at a ratio of 1:8000 in a 37°C cell culture incubator, and FBS was added at half the volume of the suspension to terminate the staining. After washing twice with PBS, 1640 culture medium containing 10% FBS was added.
[0087] 3.4 Experiment on in vitro stimulation of lymphocytes of HLA-A2+ (positive) healthy individuals by candidate neoantigens
[0088] CFSE-stained HLA-A2+ (positive) healthy individual PBMCs and prepared artificial antigen cells were added to each 96-well plate at a ratio of 1:1, and human IL-2 cytokine and new antigen peptide were added. On the 3rd and 7th days, half of the cell medium was replaced with IL-2 and peptide, and the original concentration was maintained. On the 10th day, the cells were stained with anti-human CD3 and anti-human CD8 antibodies and detected by flow cytometry. 7S-MT (candidate new antigen peptide) can induce CD8 + (Positive) T cells proliferated and had significant difference compared with the control group.
[0089] 3.5 CBA detection of IFN-γ cytokine secretion content
[0090] 12.5μl of cell supernatant was taken and incubated with CBA capture microspheres at room temperature in the dark, washed, added with detection antibody, incubated at room temperature in the dark, then added with SA-PE antibody and incubated at room temperature in the dark, washed, resuspended in PBS and transferred to flow tube for detection. The secretion of cytotoxic cytokines was detected in the cell supernatant of the 7S-MT (candidate new antigen peptide) stimulation group, and there was a significant difference compared with the control group.
[0091] Figure 4 This is a flow chart of the in vitro stimulation experiment of the immunogenicity of new antigens. Artificial antigen-presenting cells were incubated with the synthesized antigen peptides and PBMCs for 10 days, and then the proliferation of T cells and the secretion of cytotoxic cytokines in the cell supernatant were detected.
[0092] Figure 5 The results of the in vitro stimulation experiment of the immunogenicity of the new antigen, where A is the lymphocyte proliferation level and B is the cytokine secretion level. The lymphocyte proliferation level and cytokine secretion level of the in vitro stimulation experiment can reflect the immunogenicity of the new antigen. The higher the lymphocyte proliferation level and the higher the cytokine secretion level, the stronger the immunogenicity of the new antigen.
[0093] It will be easily understood by those skilled in the art that the above description is only a preferred embodiment of the present invention and is not intended to limit the present invention. Any modifications, equivalent substitutions and improvements made within the spirit and principles of the present invention should be included in the protection scope of the present invention.
Claims
1. A high-throughput immunogenic tumor neoantigen screening and identification method, characterized in that: The following steps are involved: (1) performing exon sequencing of tumor specimens and non-tumor specimens, wherein the non-tumor specimens are adjacent tissues or peripheral blood; using the exon sequencing results of the non-tumor specimens as a control, eliminating germline mutations to obtain tumor somatic mutations; performing human leukocyte antigen typing on the tumor specimens, comparing the mutant polypeptides obtained from the tumor somatic mutations with the typing results of the human leukocyte antigen typing, and obtaining human leukocyte antigen-restricted neoantigens; (2) constructing a plasmid, wherein the plasmid contains the heavy chain and light chain genes of the human leukocyte antigen described in step (1) and also contains a Flag tag; expressing the plasmid to obtain a fusion protein of the human leukocyte antigen and the Flag tag; loading the fusion protein and an antibody of a T cell co-stimulatory signal onto microspheres to construct artificial antigen presenting cells; the microspheres are sulfate latex microspheres or phospholipid microspheres; (3) incubating the human leukocyte antigen-restricted neoantigen obtained in step (1) and the artificial antigen-presenting cells obtained in step (2) so that the human leukocyte antigen-restricted neoantigen is loaded onto the human leukocyte antigen of the artificial antigen-presenting cells, and then co-incubating with T cells, wherein the surface of the T cells has the same human leukocyte antigen as that of the tumor specimen; If the T cells proliferate and cytotoxic cytokine secretion is detected, the human leukocyte antigen-restricted neoantigen is an immunogenic tumor neoantigen; If the T cells do not proliferate and / or no cytokine secretion is detected, the human leukocyte antigen-restricted new antigen is a non-immunogenic tumor new antigen.
2. The high-throughput immunogenic tumor neoantigen screening and identification method according to claim 1, characterized in that: The tumor specimen is a lung adenocarcinoma specimen, a liver cancer specimen or a colon cancer specimen.
3. The high-throughput immunogenic tumor neoantigen screening and identification method according to claim 1, characterized in that: The Flag tag is 3×Flag.
4. The high-throughput immunogenic tumor neoantigen screening and identification method according to claim 1, characterized in that: The antibody of T cell co-stimulatory signal is mouse anti-human CD28 antibody.
